Molybdenum doesn't do anything on its own. The body uses it to build one specific chemical scaffold — the molybdenum cofactor — and then slots that cofactor into the active centre of four enzymes Mendel and Kruse, 2013. That's the whole job. Knowing the four is enough to understand why this mineral shows up on a supplement label and why the marketing claims around it are usually overshooting.
- Sulfite oxidase finishes the breakdown of the sulfur amino acids in protein (methionine, cysteine) and, on top of that, cleans up the sulfites added to wines, dried apricots, processed potatoes and many medications as a preservative. When this enzyme can't keep up — almost always for a genetic reason rather than a dietary one — sulfites build up and trigger reactions ranging from wheeze to anaphylaxis in sensitive people Vally et al., 2009.
- Xanthine oxidase is the last two steps of how the body breaks down old DNA and RNA into uric acid — the molecule that crystallises in toes and joints when too much of it sits in the blood. The standard gout drug, allopurinol, works by blocking this enzyme. Molybdenum is what makes it run in the first place.
- Aldehyde oxidase helps the liver clear a list of medications and toxic by-products, working alongside the better-known cytochrome enzymes. It's quiet, but it's why several drugs reach the bloodstream at lower concentrations than their dose would predict.
- Mitochondrial amidoxime-reducing component — call it mARC — activates some prodrug medications and turns out to matter for how the liver handles fat. A common gene variant in mARC1 protects against fatty liver disease and cirrhosis in large biobank studies, a finding that has put this once-obscure enzyme on the drug-development map Emdin et al., 2020, Struwe et al., 2023.
All four roles are genuinely important. None of them are limited by how much molybdenum the average adult eats — the enzymes saturate well below typical intake, the body absorbs the mineral with high efficiency, and the kidneys send the surplus out in urine Novotny and Turnlund, 2007. The cofactor is essential; the dietary attention is not.
What happens when you actually take it
Pretty much nothing — at least nothing the literature has ever managed to measure in a healthy adult. The largest trial that included isolated molybdenum supplementation gave nearly thirty thousand Chinese adults a daily combination of vitamin C and molybdenum for over five years; mortality, cancer incidence and gastric outcomes all came back null in that arm Blot et al., 1993. The 2023 Nordic Nutrition Recommendations scoping review and the US Institute of Medicine's earlier dietary-reference report both worked through the supplementation literature and found no controlled trial in adequately fed adults that turned up a clinical benefit on energy, immunity, longevity, or anything else Sand et al., 2024, IOM, 2001.
What the literature does contain is one human case, written up in 1981, that anchors why this is an essential nutrient at all. A 24-year-old man with Crohn's disease lived for eighteen months on intravenous nutrition that was missing molybdenum, and gradually developed a constellation that turned out to be classic for the deficiency: a racing heart, headaches, night blindness, then coma. His blood chemistry told the story — methionine couldn't get fully broken down, uric acid had vanished from his urine, sulfite was pouring out the other direction. Adding 300 micrograms a day of ammonium molybdate to his feeding bag reversed it Abumrad et al., 1981. Four decades on, that case is still the only one of its kind in the published record.
The reason no second case exists is that the daily requirement — 45 micrograms in the US, 65 in Europe — is small relative to what people actually eat. A bowl of oats. A slice of whole-wheat toast with peanut butter. Half a cup of lentils. Each, on its own, clears the day's bar NIH ODS, 2024. Surveyed Americans average roughly 76 micrograms for women and 109 for men, and the European picture is similar; the soils that are genuinely molybdenum-poor are in specific endemic zones — parts of rural Henan in China and the Iranian Caspian region — and even those populations now reach reference intakes through trade EFSA, 2013, Sand et al., 2024.
Where it comes from in a normal week
Legumes are the dense source. Whole grains and nuts come next. Approximate amounts per common serving:
- Black-eyed peas, half a cup cooked: about 140 micrograms — three days of intake from one side dish.
- Kidney beans, a cup cooked: 130–185 micrograms.
- Lentils, a cup cooked: about 75 micrograms.
- Chickpeas, a cup cooked: about 70 micrograms.
- Oats, a cup cooked: about 37 micrograms.
- Almonds or cashews, a quarter cup: about 22–25 micrograms.
- Whole-wheat bread, one slice: about 12 micrograms.
Numbers from US dietary-reference tables and the NIH Office of Dietary Supplements NIH ODS, 2024, IOM, 2001. The pattern is hard to miss: anyone eating beans more than once a week, or oats most mornings, or a slice of real bread with most meals, is well past the daily mark without thinking about it. Vegetarians and vegans, who otherwise have to plan around B12, iron and omega-3, are at the top of the molybdenum distribution rather than the bottom — legumes do that work automatically.
If a supplement is what you're looking at: standalone tablets typically carry 75 to 500 micrograms per serving, multivitamins usually include 25 to 75. Either dose is biologically pointless in an adequately fed adult and, on the high end, brings a small price of its own — see contraindications below.
Three claims to set aside
"Molybdenum supports detoxification." The literal biochemistry — sulfite oxidase clears sulfite, aldehyde oxidase and mARC help process certain medications — is the toehold for this marketing line. The leap from there to "supplementing will boost detox" doesn't hold: those enzymes are already running at the speed your body needs, and extra molybdenum does not crank them up. No controlled study has shown otherwise Sand et al., 2024. The word "detox" on a supplement label, in nearly every case where it appears, is not a clinical promise.
"Molybdenum lowers uric acid and helps with gout." This one is backwards. Xanthine oxidase, the molybdenum-dependent enzyme, is the one that makes uric acid. Allopurinol, the workhorse gout drug, works by shutting it off. Populations in rural Armenia who consume soil-driven intakes of 10–15 milligrams a day have higher uric acid and gout-like symptoms, not lower ones IOM, 2001. A reader supplementing molybdenum to manage gout is acting against the mechanism, not with it.
"Molybdenum fixes sulfite sensitivity." The mechanistic story is at least plausible: if your sulfite-clearing enzyme is at the low end, more cofactor could push it back up, and a small slice of asthmatics react badly to sulfite-preserved wine and dried fruit Vally et al., 2009. The clinical evidence, however, is case reports and uncontrolled practitioner series. The most-cited modern review of sulphite reactivity does not endorse molybdenum as treatment; the standard management is avoidance plus normal asthma care. If a sulfite-sensitive reader is going to try molybdenum, low dose and a willingness to stop are the right posture — not faith in the protocol.
The one real risk: copper
Molybdenum and copper compete in the gut. At high doses, molybdenum chemically grabs the copper from your food and prevents it from being absorbed — the same chemistry the prescription drug tetrathiomolybdate uses, on purpose, to strip copper out of patients with Wilson disease Brewer et al., 2006. At supplement-aisle doses (under 500 micrograms a day) this interaction is unlikely to bite a healthy adult who eats normally. The picture changes if you're stacking — chronic high-dose molybdenum on top of zinc supplementation, a malabsorptive gut, post-bariatric anatomy, or a copper-marginal diet. Quietly tipping yourself into copper deficiency is the kind of harm that doesn't show up for months, then arrives as anaemia, low white cells, and a strange progressive nerve pattern.
The three groups for whom this is a real question
Most readers can stop here. Three subgroups have a genuine molybdenum-shaped problem and a real reason to keep reading.
If you live on tube feeding or long-term intravenous nutrition. Properly formulated parenteral nutrition includes molybdenum, but historically the only confirmed dietary deficiency in an adult — the case that anchored the daily requirement — happened in a young Crohn's patient whose intravenous bag was missing it for a year and a half Abumrad et al., 1981. This is a prescribing-team question, not a self-supplementation one. Confirm the formulation with whoever manages the prescription.
If you're a sulfite-sensitive asthmatic. Three to ten percent of adults with asthma react to the sulfites preserved into wine, dried fruit, processed potatoes, beer and several medications Vally et al., 2009. The cornerstone management is sulfite avoidance and ordinary asthma control, not molybdenum. A low-dose trial is biochemically plausible and is part of some integrative protocols, but it's not evidence-based, and skipping the avoidance step in favour of the supplement is the wrong order.
If a child in your family has been diagnosed with molybdenum cofactor deficiency or isolated sulfite oxidase deficiency. These are rare inherited disorders that present in the first days of life, not adult-onset conditions. For one subtype — molybdenum cofactor deficiency type A, caused by changes in the MOCS1 gene — there is now an approved treatment (fosdenopterin) that has dramatically improved survival when started in the first days after birth Schwarz et al., 2025. The treatment isn't oral molybdenum; the genetic block sits downstream of dietary intake. A specialist metabolic team owns this conversation.
Adjacent rabbit holes worth a look:
- Copper. The mineral on the other side of the molybdenum balance. If you supplement zinc daily or live with a malabsorptive condition, copper is the more likely thing to actually go missing.
- Sulfite sensitivity and food-additive reactions in asthma. The actual condition behind the most-Googled molybdenum claim.
- Multivitamin choice. Whether the trace-mineral panel on the back of the bottle is doing anything for you in general — molybdenum is one of several minerals that look essential on the label and are also already covered by lunch.
- Steatotic liver disease (the new name for fatty liver). The genetic protective variant in mARC1 is one of the more interesting recent leads in liver pharmacology — not the same conversation as taking molybdenum, but the same biology.
1. Substance and claimed effects
Molybdenum is an essential trace element. In humans it functions exclusively as the active centre of the molybdenum cofactor (Moco) — a tricyclic pyranopterin coordinating a single Mo atom — which is in turn the catalytic core of four enzymes: sulfite oxidase (SUOX, terminal step of sulfur amino acid catabolism, converting sulfite to sulfate), xanthine oxidoreductase (XOR, terminal two steps of purine catabolism: hypoxanthine → xanthine → urate), aldehyde oxidase (AOX1, oxidation of N-heterocyclic and aldehyde substrates including several drugs), and the two paralogs of the mitochondrial amidoxime reducing component (mARC1/mARC2, prodrug activation, reduction of N-hydroxylated metabolites, and a role in lipid/mitochondrial metabolism) Mendel and Kruse, 2013, Reiss and Hahnewald, 2016, Struwe et al., 2023. The element has no known function in humans outside these four enzymes.
The brief names four downstream consequences worth covering: sulfite metabolism, purine metabolism, detoxification, and enzyme function. All four trace to the four enzymes above. Holistic claims made for molybdenum as a nutrient-of-interest in the supplement aisle and in lay press: clearance of dietary sulfites (asthma / wine / dried fruit reactivity), prevention of uric acid build-up, generic "detoxification" support, and prevention of an unspecified deficiency syndrome. The dossier evaluates each against the literature. Reference intake: US RDA 45 µg/day adult, UL 2 000 µg/day IOM, 2001; EFSA Adequate Intake 65 µg/day EFSA, 2013; typical US intake ~76 µg/day (women) and ~109 µg/day (men) — well above either reference value NIH ODS, 2024.
2. Evidence by addressing question
Mechanism
Moco biosynthesis is a four-step pathway from GTP through cyclic pyranopterin monophosphate (cPMP) → molybdopterin (MPT) → adenylated MPT → Moco, mediated by MOCS1, MOCS2/MOCS3 and GPHN; the assembled cofactor is then inserted into the four apoenzymes, with sulfide and adenine additions producing the distinct catalytic centres of XOR/AOX/mARC versus SUOX Mendel and Kruse, 2013, Reiss and Hahnewald, 2016.
The four enzymes occupy distinct biochemical niches:
- Sulfite oxidase (mitochondrial intermembrane space) oxidises
SO32-toSO42-, completing the catabolism of cysteine and methionine and disposing of exogenous sulfite from food preservatives. Loss-of-function produces severe neonatal encephalopathy with ectopia lentis, intractable seizures, and microcephaly (isolated SUOX deficiency, or the broader Moco deficiency phenotype) — a phenotype whose severity establishes that SUOX activity is non-negotiable for survival Reiss and Hahnewald, 2016, Schwarz et al., 2025. - Xanthine oxidoreductase generates urate as the human end-product of purine catabolism. Allopurinol and febuxostat, the standard pharmacologic gout therapies, are XOR inhibitors — i.e. they act against the activity that requires molybdenum, not in favour of it.
- Aldehyde oxidase contributes to phase-I drug metabolism (e.g. methotrexate metabolism, kinase-inhibitor clearance), increasingly recognised in pharmacology because cytochrome-P450 models alone under-predict clearance for several drug classes.
- mARC1/mARC2 reduce N-hydroxylated and N-oxygenated compounds, activate amidoxime prodrugs (ximelagatran-style), and a common protective MARC1 missense variant (p.Ala165Thr) is associated with lower hepatic fat, ALT, and cirrhosis risk in large biobank analyses — implicating mARC in lipid/steatotic-liver biology beyond classical xenobiotic chemistry Emdin et al., 2020, Struwe et al., 2023.
Absorption is high (~90% at typical intake), uptake follows the sulfate/molybdate transporter, and homeostasis is regulated almost entirely by urinary excretion — explaining both why dietary excess is unusual to clinically manifest and why severe restriction is hard to engineer outside of TPN Novotny and Turnlund, 2007, IOM, 2001.
Evidence
The case for molybdenum as an essential nutrient is closed; the case for molybdenum as an intervention in adequately fed humans is essentially absent.
Essentiality. Two convergent lines: (i) the inborn errors — Moco deficiency (MOCS1/MOCS2/MOCS3/GPHN) and isolated SUOX deficiency — produce stereotyped neonatal lethality, demonstrating the absolute requirement Reiss and Hahnewald, 2016; (ii) the single published case of acquired dietary deficiency — a 24-year-old man on unsupplemented total parenteral nutrition for 18 months — developed tachycardia, tachypnoea, headache, central scotomas, night blindness and coma, with high plasma methionine, low serum and urinary urate, and high urinary thiosulfate; symptoms and biochemistry resolved on ammonium molybdate 300 µg/day Abumrad et al., 1981. This case anchors the human requirement and provides the biochemical signature reviewers refer to; no second confirmed case has been reported in the four decades since.
Intervention evidence in adequately fed adults. The Linxian General Population Nutrition Intervention Trial (29 584 adults, 5.25 years, factorial design) included a Factor C arm of vitamin C 120 mg plus molybdenum 30 µg/day; this arm produced no statistically significant reduction in total mortality, cancer mortality, oesophageal cancer or gastric cancer Blot et al., 1993. The only Linxian arm with a positive mortality signal was Factor D (β-carotene + α-tocopherol + selenium), unrelated to molybdenum. No subsequent RCT has tested isolated molybdenum supplementation against a clinically meaningful end-point in adequately fed adults — the literature reviewed for both the 2001 US DRI report and the 2023 Nordic Nutrition Recommendations identifies no such trial IOM, 2001, Sand et al., 2024.
Effect size, where any exists. A handful of small balance and kinetic studies in healthy men have characterised absorption and turnover (e.g. Novotny and Turnlund, 2007) but report no clinical end-points. Sulfite-sensitivity series and case reports describing improvement on 100–500 µg/day molybdenum are uncontrolled, small, and not replicated in any placebo-controlled trial; the systematic review of sulphite-additive reactivity does not list molybdenum among evidence-supported interventions Vally et al., 2009.
Practicalities
Molybdenum is densest in legumes; whole grains, nuts and organ meats follow. Approximate Moco content per serving from USDA and dietary-reference tables: black-eyed peas ~143 µg per half cup of beans (often the highest single source on a per-serving basis); kidney beans ~130–185 µg/cup; lentils ~74 µg/cup; chickpeas ~70 µg/cup; oats ~37 µg/cup; quinoa ~30 µg/cup; almonds ~25 µg per quarter cup; cashews ~22 µg per quarter cup; one slice of whole-wheat bread ~12 µg NIH ODS, 2024, IOM, 2001. Soil molybdenum varies regionally (low in some parts of north-central China, including the high-oesophageal-cancer Linxian region; replete across most of Europe and North America), but at the population level mixed-diet intakes converge well above the US RDA across surveyed countries Sand et al., 2024, EFSA, 2013.
Supplemental molybdenum is available as sodium molybdate or ammonium molybdate, typically 75–500 µg per tablet; multivitamins commonly include 25–75 µg. Cost is trivial relative to other supplements. The clinically used form tetrathiomolybdate (an orphan-drug copper-chelating agent for Wilson disease and an investigational anti-angiogenic) is not the same product as the over-the-counter supplement and is not orderable through retail channels Brewer et al., 2006.
Contraindications
The UL for adults is 2 000 µg/day, set on animal reproductive/growth data because no consistent human end-point allowed a tighter limit IOM, 2001. The principal mechanism of concern at chronic supraphysiological intake is copper antagonism: dietary molybdate and sulfide combine in the gut to form thiomolybdates that bind copper and impair absorption — the same chemistry exploited therapeutically by tetrathiomolybdate in Wilson disease, which can reduce ceruloplasmin and serum copper substantially within weeks at pharmacologic doses Brewer et al., 2006. At supplement-aisle doses (≤500 µg/day) clinically meaningful copper depletion is unlikely in copper-replete adults, but stacking with high-sulfur diets or with chronic high-dose use plausibly tightens the margin.
A single published acute-toxicity case describes an adult man who consumed 300–800 µg/day of molybdenum over 18 days (cumulative ~13.5 mg) and presented with acute psychosis, hallucinations and seizures; causality is uncertain and unreplicated NIH ODS, 2024. Endemic-high-molybdenum populations (parts of Armenia, ~10–15 mg/day from soil) have reported elevated urate and a gout-like syndrome, but the data are observational and ecological IOM, 2001. Pregnancy/lactation RDA is 50 µg/day; supplementation above 100 µg/day during pregnancy lacks safety data and is not recommended outside clinical indication NIH ODS, 2024.
Misconceptions
Three claims appear repeatedly in lay marketing and warrant explicit rebuttal:
- "Molybdenum helps detoxify." The literal biochemistry (SUOX clears sulfite, AOX/mARC contribute to xenobiotic phase-I) is the basis for the marketing claim, but at the population scale every adult already runs these reactions at adequate capacity from dietary intake. There is no controlled evidence that supplementation above dietary adequacy increases SUOX/AOX/mARC activity in adequately fed adults, and the framing collapses normal enzyme activity into a marketing concept that does not map onto a clinical end-point Sand et al., 2024.
- "Molybdenum prevents/treats sulfite sensitivity." The mechanistic story (low SUOX activity → poor sulfite clearance → bronchoconstriction in sulfite-sensitive asthmatics) is biochemically coherent; the question is whether a meaningful subset of sulfite-sensitive patients are actually molybdenum-limited at SUOX. The published clinical literature consists of case reports and uncontrolled series; the most-cited modern review of sulphite reactivity does not endorse molybdenum supplementation as an evidence-based treatment Vally et al., 2009. The mainstream management is sulphite avoidance plus usual asthma care.
- "Molybdenum lowers uric acid / prevents gout." Inverted: molybdenum is the cofactor for XOR, the enzyme whose inhibition lowers urate (allopurinol mechanism). Above-RDA molybdenum intake at the population level is associated with higher serum urate, not lower; high-molybdenum endemic regions describe gout-like presentations IOM, 2001. A reader supplementing molybdenum hoping to manage gout is acting against mechanism.
Audience
Three subgroups have a real molybdenum question; the rest do not.
- Long-term TPN patients. Adequately formulated parenteral nutrition includes molybdenum (typical 19–25 µg/day adult provision); unsupplemented home TPN remains the only documented acquired-deficiency vector and is a prescriber concern, not a consumer one Abumrad et al., 1981, NIH ODS, 2024.
- Sulfite-sensitive asthmatics. ~3–10% of adult asthmatics, lower in the general population Vally et al., 2009. The relevant management is sulphite-additive avoidance and asthma control; supplemental molybdenum is plausible but unproven, and is not a substitute for the avoidance/clinical-care pathway.
- Families with an inborn error of Moco metabolism. MoCD type A (MOCS1) now has FDA-approved treatment with cyclic pyranopterin monophosphate (fosdenopterin); a 2025 international cohort reports markedly improved survival when treatment is initiated within days of birth, though intellectual disability often persists. Types B/C and isolated SUOX deficiency remain untreated, and are not affected by oral molybdenum supplementation — the genetic block is downstream of dietary uptake Reiss and Hahnewald, 2016, Schwarz et al., 2025.
Vegetarians and vegans are over-represented at the high end of intake (legumes and whole grains being the densest sources); no plant-based subgroup risk exists for this nutrient, distinguishing it from B12, iron, omega-3, iodine.
Stakes
For an adequately fed reader the stakes of inattention are essentially nil: marginal intake variation within the normal dietary range has no demonstrated clinical end-point. For long-term TPN patients, omission produces the Abumrad signature (high methionine, low urate, sulfite intolerance, eventual neurological signs) within months Abumrad et al., 1981. For copper-replete adults consuming chronic high-dose molybdenum supplements, the relevant stake is iatrogenic copper depletion — a known mechanism exploited at higher doses in Wilson disease and a plausible (if unlikely) consequence of self-prescribed supplementation, particularly when combined with zinc or high-sulfur diets Brewer et al., 2006.
Payoff
No demonstrated supplementation payoff in adequately fed adults: no positive RCT on a clinical end-point, no consistent observational signal at intakes above the RDA Sand et al., 2024, IOM, 2001. The payoff of attention to this entry is editorial rather than physiological: a reader who internalises the case can deprioritise a supplement-aisle line item and redirect the money or worry elsewhere.
Out-of-scope
Tetrathiomolybdate as an investigational anti-angiogenic in oncology (separate pharmacology, prescription pathway). Plant molybdenum biology (nitrogen fixation in legume root nodules, agricultural biofortification). Detailed pharmacogenomics of AOX1 in drug clearance. mARC1 variants and metabolic-associated steatotic liver disease (likely warrants its own entry once the therapeutic programme matures) Emdin et al., 2020.
3. The credibility range
Optimist case
Molybdenum's essentiality is undisputed and the four enzymes it serves cover an unusual breadth — sulfur amino acid disposal, purine catabolism, xenobiotic clearance, lipid handling. Recent mARC1 genetics genuinely points at a metabolic-liver-disease lever that was unrecognised a decade ago, and the mARC drug-target programme is active. Practitioner reports of sulfite-sensitivity improvement on supplementation are biochemically coherent and clinically inexpensive to trial in a willing patient. The UL is generous (2 mg/day, ~44× the RDA), suggesting the safety margin around routine supplementation is wide. A reader with a niche use case (sulphite reactivity refractory to avoidance, undiagnosed TPN history, a sense that legumes are minimal in their diet) has a low-cost, low-risk warrant to try low-dose supplementation.
Skeptic case
The optimist case rests on biochemistry, not clinical outcomes. The single positive intervention end-point in healthy adults is the Abumrad TPN case — a literal deficiency, not a supplementation trial. The largest RCT including isolated molybdenum (Linxian Factor C) was null. The most-cited sulphite-additive review does not endorse molybdenum. No mortality, morbidity, or biomarker signal has been reproduced in adequately fed adults at intakes above the RDA. Population intakes already exceed both the US RDA and the EFSA AI in surveyed cohorts, leaving no plausible deficit to fill with supplementation. The copper-antagonism mechanism is sufficient to make chronic high-dose supplementation actively undesirable in copper-replete adults. The "detoxification" marketing is unanchored.
Author's call
Lands firmly on the skeptic side. Molybdenum is essential — but its essentiality is met by ordinary food, with margin to spare, across every surveyed population outside soil-deficient endemic zones. There is no defensible supplementation case in the typical reader. The honest editorial job is to (i) lock the biology so the reader understands why it appears on multivitamin labels, (ii) make clear that the RDA is met by lunch, (iii) flag the niche subgroups where the question is real, and (iv) name copper antagonism as the asymmetric risk of supplementation. The entry's evidence dimension reflects this split: the biological/essentiality evidence is high, but the intervention evidence in adequately fed adults is low, and the meta scoring follows the intervention.
4. Stakeholder and incentive map
- Supplement industry includes molybdenum in multivitamins and sells stand-alone formulations marketed for "detoxification", "sulphite tolerance" and (incorrectly) "uric acid balance". Incentive: low-cost ingredient with high perceived completeness on a supplement-facts panel.
- Practitioner naturopathic/functional medicine recommends molybdenum for sulphite sensitivity, food-chemical intolerance, and "MTHFR" / "methylation" frameworks; uncontrolled clinical experience drives strong individual conviction.
- Mainstream nutrition bodies (US IOM, EFSA, Nordic NNR, NIH ODS) have repeatedly concluded that deficiency in free-living adults is undocumented and supplementation is unnecessary; their incentive is conservative population guidance.
- Rare-disease industry (Origin Biosciences/Sentynl, now BridgeBio for fosdenopterin) carries an active programme for MoCD type A — disjoint from the consumer-supplement market but the source of most recent visibility for the cofactor's biology Schwarz et al., 2025.
- Pharma/research interest in mARC is rising as an emerging drug target for steatotic liver disease, distinct from the supplement story but adjacent in the literature Struwe et al., 2023, Emdin et al., 2020.
5. Population variability
- Sex/age: US RDA flat across adults at 45 µg/day; pregnancy/lactation 50 µg/day; intake in surveyed cohorts is sex-asymmetric only because men eat more food.
- Diet pattern: Vegetarian and Mediterranean patterns trend high (legume-dense). Highly processed / low-legume diets trend lower but still above RDA in surveyed cohorts.
- Soil geochemistry: Locally low-Mo regions (parts of north-central China, including the Linxian Henan basin; some Iranian Caspian-littoral zones) historically correlated with high oesophageal cancer rates, although the causal contribution of molybdenum specifically is unsettled and Linxian Factor C did not separate it out Blot et al., 1993.
- Copper status: Copper-deficient or copper-marginal adults (post-bariatric, chronic zinc supplementers, malabsorptive states) are the population in whom molybdenum supplementation is most plausibly net-harmful via the thiomolybdate-copper antagonism.
- Sulphite-sensitive asthmatics: 3–10% of adult asthmatics by clinical reports Vally et al., 2009; whether any subset is functionally Mo-limited at SUOX is the open question.
- Inborn errors: MoCD ~1:100 000–1:200 000 estimated incidence; isolated SUOX deficiency rarer still Reiss and Hahnewald, 2016.
6. Knowledge gaps
- No placebo-controlled trial of supplemental molybdenum in sulphite-sensitive asthmatics. A small, well-designed crossover trial would settle the most clinically interesting open claim.
- The functional Mo-SUOX dose-response in adults at the lower end of dietary intake has not been mapped — i.e. whether at intakes near the RDA, SUOX is rate-limited under high sulphite-load conditions.
- The mARC1-A165T metabolic protective signal needs mechanistic translation: is the protective allele a gain- or loss-of-function, and does dietary molybdenum modulate the phenotype? Current human data is genetic-association only Emdin et al., 2020.
- No modern (post-2000) confirmed dietary deficiency case outside the original Abumrad TPN report.
- Chronic-low-dose human studies of supplemental molybdenum's effect on serum copper and ceruloplasmin are absent; current safety inference draws on Wilson-disease pharmacology at much higher doses Brewer et al., 2006.
The topic brief named "sulfite and purine metabolism, detoxification, and enzyme function" as worth covering. The article covers all four — sulfite metabolism (sulfite oxidase, and the sulfite-sensitivity claim), purine metabolism (xanthine oxidase / gout misconception), enzyme function (the four-enzyme tour in mechanism), and detoxification (handled by debunking the marketing line rather than endorsing it). No silent narrowing.
- Holistic dimension scoring. All eight benefit dimensions scored 0 — not because molybdenum is biologically inert (the cofactor is non-negotiable for life), but because in the adequately fed adult who is the catalogue's typical reader, marginal attention to molybdenum delivers no measurable effect on any of them. The rating-doc requires scoring against what the substance actually delivers; for this reader, that is nothing. The honest framing of an entry that says "you're fine; ignore the supplement" is a zero column with a clearly argued evidence call, not a manufactured 1 somewhere.
- Evidence score 3, not higher. The biology is settled (would support 5 on the mechanism side) but the actionable claim "this entry's intervention does anything in adequately fed adults" rests on a thin supplementation literature plus the null Linxian arm. The 3 reflects the strength of the reader-facing claim ("eat normal food, skip the pill"), which is well-anchored — not the strength of the molecular biology, which would otherwise inflate the dimension.
- Action
know. Consideredavoidfor the supplementation framing; rejected because the entry's primary teaching is biological awareness rather than "don't ingest."Knowwith a debunking layer felt truer to the editorial position. - Applicability lifted to 3 on the avoidance-audience reasoning in meta.md §6: the addressable audience is broader than current molybdenum-supplement-buyers, because anyone who has ever looked at a multivitamin label or wondered about a "detox" claim is in scope.
- Dream narrative skipped. Overall score ~12, well below the 40 threshold. The honest hook is debunking ("save your money"), and a dream cascade would ring false. Dek and tagline written straight per dream-narrative.md §1.
- Category placement:
supplements. The substance is technically a food-derived nutrient, but the practical reader question — "should I be taking this?" — sits in the supplements aisle, and the entry's role is to push back against that framing. Placement infoodwould mis-signal that this is about choosing what to eat. - Contraindications array left empty. No structural unsafe-population marker applies, because the entry does not recommend an intervention; the copper-antagonism warning sits inside the body where it's load-bearing rather than as a structural flag.
- Separate-entry candidates worth tracking:
- mARC1 variants and steatotic liver disease — likely earns its own entry once the drug-target programme matures. Currently genetic-association data only.
- Tetrathiomolybdate in oncology — distinct prescription pharmacology; out of scope here.
- Sulfite sensitivity as a standalone allergy/asthma entry rather than a fringe of this one — the condition has its own clinical pathway and warrants the entry.
- Future links to wire when the entries exist: a copper entry (the symmetric counterweight), a multivitamin-choice entry (where to put this in the broader supplement-skeptic frame), and the sulfite-sensitivity entry above.
- Hard call: the sulfite-sensitivity supplementation claim. Wanted to flatly recommend against it; settled on "biochemically plausible but not evidence-based, low-dose trial is a defensible move with avoidance as the cornerstone." The 1981 orthomolecular literature on this is not citable by spec standards. If a placebo-controlled trial ever lands, revisit this section.
Molybdenum
The essentiality of the four molybdoenzymes (SUOX, XOR, AOX1, mARC1/2) is undisputed and well-characterised mechanistically (Reiss 2016; Mendel 2013; Struwe 2023). US and EFSA dietary reference values are anchored on multiple balance/kinetic studies (IOM 2001; EFSA 2013; Novotny 2007), and population intake data show the RDA is exceeded across surveyed cohorts (NIH ODS 2024). The single documented case of acquired dietary deficiency (Abumrad 1981) was a long-term TPN patient, not a free-living adult. The Linxian Factor C arm (Blot 1993) and the 2023 Nordic Nutrition Recommendations scoping review (Sand 2024) identify no supplementation benefit on a clinical end-point in adequately fed adults. The reader-facing claim — essential, but already covered by ordinary food — is firmly established; the supplementation claim is not.